FDA Approves Belantamab Mafodotin-blmf for R/R Multiple Myeloma

Belantamab mafodotin-blmf (BLENREP®, GlaxoSmithKline) was recently FDA approved for adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have previously failed four therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Approval was based on DREAMM-2 (NCT03525678), an open-label, multicenter trial that enrolled 293 patients with R/R MM with disease progression after three or more lines of prior therapy and who were refr...
Continue reading

Lenalidomide for High-Risk Smoldering Multiple Myeloma

​In results soon to be presented at the American Society of Clinical Oncology Annual Meeting (ASCO), the E3A06 phase 3 clinical trial has found that single-agent lenalidomide (Revlimid®, Celgene) improves progression-free survival in patients with asymptomatic high-risk smoldering multiple myeloma (SMM). Smoldering multiple myeloma is a pre-cancerous, asymptomatic clonal plasma cell disorder with a high chance of progressing to multiple myeloma. Treatment for this condition has typically been li...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.